AIGEN Sciences, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
AIGEN Sciences, Inc. - overview
Established
2021
Location
Seoul, -, South Korea
Primary Industry
Pharmaceuticals
About
Based in Seoul, South Korea, and founded in 2021 by CEO Jaewoo Kang, AIGEN Sciences, Inc. , a. k. a.
AIGEN Sciences is an AI-based new drug development company that provides an AI platform technology based on transcriptome data used to screen and design drugs with novel structures. In October 2022, AIGEN Sciences raised KRW 4. 2 billion in a pre-series A funding from Bluepoint Partners, Korea University Technology Holdings, Medy-Tox Inc. , Partners Investment, and Quad Asset Management.
The company’s product line includes AIG-Onco1, AIG-Onco2, AIG-Onco3, and AIG-Onco1 for the treatment of pancreatic/colon cancer, and solid cancer. In addition, AIGEN Sciences’s partnered research and development pipeline includes AIG-Immune1 w/ and AIG-Onco5 w/ for the treatment of autoimmune disease and lung cancer. The firm’s AI-based drug development platform can screen and design new structured drugs that induce transcriptome changes like disease-targeted inhibitors with transcriptome data-driven AI technology, minimizing the side effects that the drug causes on unintended off-targets. AIGEN Sciences plans to use its proceeds from October 2022 funding to expand its virtual transcriptome map technology, build a structure-based linked molecular design technology platform, recruit additional artificial intelligence, synthesis, and pharmacology/bio researchers, and accelerate the development of its new drug pipeline.
Current Investors
Partners Investment, Bluepoint Partners, Quad Asset Management
Primary Industry
Pharmaceuticals
Sub Industries
Bioinformatics, Healthcare IT, Pharmaceutical Research & Development
Website
www.aigensciences.com
Verticals
Artificial Intelligence, HealthTech, Manufacturing
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
AIGEN Sciences, Inc. - financials
| Fiscal Year Ended | Dec 31, 2021 | Dec 31, 2022 |
|---|---|---|
| Revenue (USD) | - | - |
| % Revenue Growth (YoY) | - | - |
| EBITDA (USD) | - | - |
| Operating Income (USD) | - | - |
| Operating Margin | - | - |
| % EBITDA Margin | - | - |
| NET Income (USD) | - | - |
| % Net Margin | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.